% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kratochwil:276331,
      author       = {C. Kratochwil and W. P. Fendler$^*$ and M. Eiber and M. S.
                      Hofman and L. Emmett and J. Calais and J. R. Osborne and A.
                      Iravani and P. Koo and L. Lindenberg and R. P. Baum and M.
                      F. Bozkurt and R. C. Delgado Bolton and S. Ezziddin and F.
                      Forrer and R. J. Hicks and T. A. Hope and L. Kabasakal and
                      M. Konijnenberg and K. Kopka$^*$ and M. Lassmann and F. M.
                      Mottaghy and W. J. G. Oyen and K. Rahbar and H. Schoder and
                      I. Virgolini and L. Bodei and S. Fanti and U. Haberkorn and
                      K. Hermann$^*$},
      title        = {{J}oint {EANM}/{SNMMI} procedure guideline for the use of
                      177{L}u-labeled {PSMA}-targeted radioligand-therapy
                      (177{L}u-{PSMA}-{RLT}).},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {50},
      number       = {9},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2023-01061},
      pages        = {2830-2845},
      year         = {2023},
      note         = {2023 Jul;50(9):2830-2845},
      abstract     = {Prostate-specific membrane antigen (PSMA) is expressed by
                      the majority of clinically significant prostate
                      adenocarcinomas, and patients with target-positive disease
                      can easily be identified by PSMA PET imaging. Promising
                      results with PSMA-targeted radiopharmaceutical therapy have
                      already been obtained in early-phase studies using various
                      combinations of targeting molecules and radiolabels.
                      Definitive evidence of the safety and efficacy of
                      [177Lu]Lu-PSMA-617 in combination with standard-of-care has
                      been demonstrated in patients with metastatic
                      castration-resistant prostate cancer, whose disease had
                      progressed after or during at least one taxane regimen and
                      at least one novel androgen-axis drug. Preliminary data
                      suggest that 177Lu-PSMA-radioligand therapy (RLT) also has
                      high potential in additional clinical situations. Hence, the
                      radiopharmaceuticals [177Lu]Lu-PSMA-617 and
                      $[177Lu]Lu-PSMA-I\&T$ are currently being evaluated in
                      ongoing phase 3 trials. The purpose of this guideline is to
                      assist nuclear medicine personnel, to select patients with
                      highest potential to benefit from 177Lu-PSMA-RLT, to perform
                      the procedure in accordance with current best practice, and
                      to prepare for possible side effects and their clinical
                      management. We also provide expert advice, to identify those
                      clinical situations which may justify the off-label use of
                      [177Lu]Lu-PSMA-617 or other emerging ligands on an
                      individual patient basis.},
      keywords     = {EANM/SNMMI (Other) / PSMA (Other) / [177Lu]Lu-PSMA-617
                      (Other)},
      cin          = {ED01 / DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37246997},
      doi          = {10.1007/s00259-023-06255-8},
      url          = {https://inrepo02.dkfz.de/record/276331},
}